Clinical Trial

Adjunctive, Low-Dose tPA in Primary PCI for STEMI

Study Description

Adjunctive, Low-dose tPA in Primary PCI for STEMI

STRIVE will evaluate the use of adjunctive, low-dose intracoronary tissue plasminogen activator during primary percutaneous coronary intervention (PCI) for patients with ST elevation myocardial infarction (STEMI) in reducing the incidence of post-procedural myocardial blush (MBG) grade 0/1 or distal embolization.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - tissue plasminogen activator

Recombinant tPA is a fibrin-specific 2nd generation plasminogen activator and thrombolytic drug.

Saline

Placebo

Additional Information

Official Study Title

Adjunctive, Low-dose Intracoronary Recombinant Tissue Plasminogen Activator (tPA) Versus Placebo for Primary PCI in Patients With ST-segment Elevation Myocardial Infarction

Clinical Trial ID

NCT03335839

ParticipAid ID

Pe9K4b